MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases
- PMID: 30126419
- PMCID: PMC6102798
- DOI: 10.1186/s13000-018-0733-9
MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases
Abstract
Background: Myxofibrosarcoma (MFS) is one of the most common soft tissue sarcomas. Previous studies have shown that MET protein overexpressed in MFS patients and can serve as a prognostic factor. The reasons for MET protein overexpression include amplification of the MET gene, which is located on chromosome 7q. Triggered by an index case harboring chromosome 7 polysomy rather than MET gene amplification in myxofibrosarcoma, we investigated chromosome 7 polysomy in more cases.
Methods: Immunohistochemistry and fluorescence in situ hybridization (FISH) were performed in 30 MFS cases (including 2 epithelioid variant) to detect the expression of MET protein and gene status.
Results: MET was overexpressed in 14 cases out of 30, while thirteen cases were in higher FNCLCC grades (Grade 2-3). FISH showed that 11 cases having 3 signals on average of Met and more than 3 signals (Mean: 4.6) of centromere 7q (CEP7q). The MET/CEP7 ratio was about 0.65 on average, suggesting that chromosome 7 polysomy, rather than Met gene amplification, leading to the overexpression of MET protein in MFS. MET overexpression and chromosome 7 polysomy are positively correlated with higher Ki-67 index and higher grade and might have a high risk of local recurrence and metastasis.
Conclusions: It might reveals another explain of MET overexpression in myxofibrosarcoma, providing a clue for the therapy of MFS.
Keywords: Chromosome 7 polysomy; FISH; MET; Myxofibrosarcoma.
Conflict of interest statement
Ethics approval and consent to participate
The study procedures were approved by the Ethics Committee of Xijing Hospital (reference numbe: KY-20171981). No consent was needed.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures



Similar articles
-
The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.Hum Pathol. 2017 Jun;64:98-105. doi: 10.1016/j.humpath.2017.04.002. Epub 2017 Apr 17. Hum Pathol. 2017. PMID: 28428108
-
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.Breast Cancer Res. 2005;7(2):R267-73. doi: 10.1186/bcr996. Epub 2005 Jan 26. Breast Cancer Res. 2005. PMID: 15743507 Free PMC article.
-
[Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):584-8. Zhonghua Bing Li Xue Za Zhi. 2006. PMID: 17134563 Chinese.
-
Myxofibrosarcoma of the mandible: a case report and review of the literature.BMC Oral Health. 2020 Apr 16;20(1):113. doi: 10.1186/s12903-020-01094-7. BMC Oral Health. 2020. PMID: 32299394 Free PMC article. Review.
-
Sclerosing epithelioid fibrosarcoma: a cytogenetic, immunohistochemical, and ultrastructural study of an unusual histological variant.Cancer Genet Cytogenet. 2000 Jun;119(2):127-31. doi: 10.1016/s0165-4608(99)00225-3. Cancer Genet Cytogenet. 2000. PMID: 10867148 Review.
Cited by
-
Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives.Diagnostics (Basel). 2023 Sep 22;13(19):3022. doi: 10.3390/diagnostics13193022. Diagnostics (Basel). 2023. PMID: 37835765 Free PMC article. Review.
-
Molecular profiling of soft-tissue sarcomas with FoundationOne® Heme identifies potential targets for sarcoma therapy: a single-centre experience.Ther Adv Med Oncol. 2021 Jul 25;13:17588359211029125. doi: 10.1177/17588359211029125. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34367342 Free PMC article.
-
Report of two primary renal tumors with myxoid features. Differential diagnosis between benign and malignant entities.Pathologica. 2021 Dec;113(6):427-435. doi: 10.32074/1591-951X-180. Pathologica. 2021. PMID: 34974548 Free PMC article.
-
Giant Myxofibrosarcoma in the Lower Limb: An Overview of Diagnostic and Clinical Management.Diagnostics (Basel). 2024 Jun 19;14(12):1298. doi: 10.3390/diagnostics14121298. Diagnostics (Basel). 2024. PMID: 38928713 Free PMC article. Review.
-
Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma.Virchows Arch. 2022 Oct;481(4):1-17. doi: 10.1007/s00428-022-03358-9. Epub 2022 Jun 15. Virchows Arch. 2022. PMID: 35705750
References
-
- Yang Y, Wu N, Shen J, Teixido C, Sun X, Lin Z, et al. MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer. Gastric Cancer. 2015; - PubMed
-
- Paliga A, Marginean H, Tessier-Cloutier B, Purgina B, Jonker D, Marginean EC. The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas. American journal of clinical oncology. 2015; - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous